Halozyme Therapeutics (NASDAQ:HALO) CFO Nicole Labrosse Sells 2,227 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. This trade represents a 9.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Nicole Labrosse also recently made the following trade(s):

• On Wednesday, September 10th, Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00.

Halozyme Therapeutics Trading Down 0.9%

NASDAQ HALO opened at $77.57 on Wednesday. The business’s 50-day moving average price is $67.96 and its two-hundred day moving average price is $61.33. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $79.50. The firm has a market capitalization of $9.07 billion, a PE ratio of 17.75, a price-to-earnings-growth ratio of 0.43 and a beta of 1.19. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. During the same period in the prior year, the business posted $0.91 earnings per share. The firm’s revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on HALO. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price target on the stock. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Morgan Stanley increased their price target on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, August 18th. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Finally, Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $68.22.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds have recently modified their holdings of the company. DLD Asset Management LP bought a new stake in Halozyme Therapeutics during the second quarter worth $650,250,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after purchasing an additional 1,425,674 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $51,295,000. Los Angeles Capital Management LLC raised its position in Halozyme Therapeutics by 951.8% in the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock worth $50,650,000 after acquiring an additional 881,094 shares during the period. Finally, Norges Bank bought a new stake in Halozyme Therapeutics in the second quarter worth about $45,027,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.